Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations

Jay R. Shapiro, E. Michael Lewiecki

Research output: Contribution to journalArticle

Abstract

Hypophosphatasia (HPP) is a rare inherited disorder of bone affecting approximately 500 to 600 known individuals in the United States. HPP is the result of mutations involving the gene for tissue nonspecific alkaline phosphatase. Five clinical types of HPP are recognized. The clinical presentation of HPP varies from devastating prenatal intrauterine disease to mild manifestations in adulthood. In adults, main clinical involvement includes early loss of primary or secondary teeth, osteoporosis, bone pain, chondrocalcinosis, and fractures. Treatment for HPP is limited. Asfotase alfa is a subcutaneously administered synthetic human alkaline phosphatase that is approved for treatment of patients, including adults, with perinatal/infantile- and juvenile-onset HPP. However, guidelines for the treatment of adults with HPP are not available. This discussion addresses diagnostic and treatment considerations for adults with HPP.

LanguageEnglish (US)
Pages1977-1980
Number of pages4
JournalJournal of Bone and Mineral Research
Volume32
Issue number10
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Hypophosphatasia
Alkaline Phosphatase
Therapeutics
Chondrocalcinosis
Bone and Bones
Osteoporosis
Adult Hypophosphatasia
Tooth
Guidelines
Pain
Mutation

Keywords

  • ALKALINE PHOSPHATASE
  • ASFOTASE ALFA
  • HYPOPHOSPHATASIA
  • OSTEOMALACIA
  • OSTEOPOROSIS

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Hypophosphatasia in Adults : Clinical Assessment and Treatment Considerations. / Shapiro, Jay R.; Lewiecki, E. Michael.

In: Journal of Bone and Mineral Research, Vol. 32, No. 10, 01.10.2017, p. 1977-1980.

Research output: Contribution to journalArticle

@article{5845d57b613342458e27069b3df70937,
title = "Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations",
abstract = "Hypophosphatasia (HPP) is a rare inherited disorder of bone affecting approximately 500 to 600 known individuals in the United States. HPP is the result of mutations involving the gene for tissue nonspecific alkaline phosphatase. Five clinical types of HPP are recognized. The clinical presentation of HPP varies from devastating prenatal intrauterine disease to mild manifestations in adulthood. In adults, main clinical involvement includes early loss of primary or secondary teeth, osteoporosis, bone pain, chondrocalcinosis, and fractures. Treatment for HPP is limited. Asfotase alfa is a subcutaneously administered synthetic human alkaline phosphatase that is approved for treatment of patients, including adults, with perinatal/infantile- and juvenile-onset HPP. However, guidelines for the treatment of adults with HPP are not available. This discussion addresses diagnostic and treatment considerations for adults with HPP.",
keywords = "ALKALINE PHOSPHATASE, ASFOTASE ALFA, HYPOPHOSPHATASIA, OSTEOMALACIA, OSTEOPOROSIS",
author = "Shapiro, {Jay R.} and Lewiecki, {E. Michael}",
year = "2017",
month = "10",
day = "1",
doi = "10.1002/jbmr.3226",
language = "English (US)",
volume = "32",
pages = "1977--1980",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Hypophosphatasia in Adults

T2 - Journal of Bone and Mineral Research

AU - Shapiro,Jay R.

AU - Lewiecki,E. Michael

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Hypophosphatasia (HPP) is a rare inherited disorder of bone affecting approximately 500 to 600 known individuals in the United States. HPP is the result of mutations involving the gene for tissue nonspecific alkaline phosphatase. Five clinical types of HPP are recognized. The clinical presentation of HPP varies from devastating prenatal intrauterine disease to mild manifestations in adulthood. In adults, main clinical involvement includes early loss of primary or secondary teeth, osteoporosis, bone pain, chondrocalcinosis, and fractures. Treatment for HPP is limited. Asfotase alfa is a subcutaneously administered synthetic human alkaline phosphatase that is approved for treatment of patients, including adults, with perinatal/infantile- and juvenile-onset HPP. However, guidelines for the treatment of adults with HPP are not available. This discussion addresses diagnostic and treatment considerations for adults with HPP.

AB - Hypophosphatasia (HPP) is a rare inherited disorder of bone affecting approximately 500 to 600 known individuals in the United States. HPP is the result of mutations involving the gene for tissue nonspecific alkaline phosphatase. Five clinical types of HPP are recognized. The clinical presentation of HPP varies from devastating prenatal intrauterine disease to mild manifestations in adulthood. In adults, main clinical involvement includes early loss of primary or secondary teeth, osteoporosis, bone pain, chondrocalcinosis, and fractures. Treatment for HPP is limited. Asfotase alfa is a subcutaneously administered synthetic human alkaline phosphatase that is approved for treatment of patients, including adults, with perinatal/infantile- and juvenile-onset HPP. However, guidelines for the treatment of adults with HPP are not available. This discussion addresses diagnostic and treatment considerations for adults with HPP.

KW - ALKALINE PHOSPHATASE

KW - ASFOTASE ALFA

KW - HYPOPHOSPHATASIA

KW - OSTEOMALACIA

KW - OSTEOPOROSIS

UR - http://www.scopus.com/inward/record.url?scp=85031116898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031116898&partnerID=8YFLogxK

U2 - 10.1002/jbmr.3226

DO - 10.1002/jbmr.3226

M3 - Article

VL - 32

SP - 1977

EP - 1980

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 10

ER -